Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MIS18A antisense RNA 1 (MIS18A-AS1) is a non-coding transcript produced from the antisense strand of the MIS18A gene locus. Like other antisense lncRNAs, MIS18A-AS1 is likely involved in regulating the expression of its cognate sense gene (MIS18A), potentially via altering chromatin accessibility or transcriptional interference, or by acting as a competing endogenous RNA (ceRNA) for microRNAs. Such lncRNAs can influence gene expression in a cis- or trans-acting fashion, but precise biological characterization of MIS18A-AS1 remains limited. There is no evidence that MIS18A-AS1 is a druggable therapeutic target, a receptor, enzyme, transporter, or classic molecular entity; its main significance rests in potential gene regulatory functions and roles in chromatin biology typical of other antisense lncRNAs[4][2]. MIS18A-AS1 is not a protein, enzyme, receptor, or transporter. It is a long non-coding RNA, specifically an antisense transcript[4]. There is no direct evidence associating MIS18A-AS1 with drugs, mechanisms of action for drug targeting, or biomarker use. This distinguishes it from the protein product MIS18A, which is a centromere-associated factor with roles in mitosis and tumorigenesis (but is not the same as MIS18A-AS1)[5]. Molecular classification is best assigned as "long non-coding RNA" and "antisense RNA." It does not fit typical drug target categories such as receptor, transporter, etc. No error or misspelling in target assignment; the main limitation is that this is not a classical therapeutic/protein-coding target. MIS18A antisense RNA 1 (MIS18A-AS1) is a lncRNA with a primary role in regulation of gene expression, not a classic therapeutic target, and should be classified under non-coding RNA/antisense RNA designations[4][2].
Not applicable (no direct targeting drugs/therapies); in a broader context, antisense oligonucleotides (ASOs) can modulate lncRNA activity by hybridizing and inducing degradation or blocking function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MIS18A antisense RNA 1 (non-protein coding) (MIS18A-AS1).